Lifetime exposure to estrogens and Parkinson's disease in California teachers

被引:56
作者
Gatto, N. M. [1 ]
Deapen, D. [5 ]
Stoyanoff, S. [5 ]
Pinder, R. [5 ]
Narayan, S. [2 ]
Bordelon, Y. [4 ]
Ritz, B. [2 ,3 ,4 ]
机构
[1] Loma Linda Univ, Dept Epidemiol Biostat & Populat Med, Loma Linda, CA 92350 USA
[2] Univ Calif Los Angeles, Dept Epidemiol, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, Dept Environm Hlth Sci, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA
[5] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90033 USA
关键词
Estrogen; Reproductive; Hormone therapy; Parkinson's; Menopause; REPRODUCTIVE FACTORS; POSTMENOPAUSAL ESTROGEN; PREMENOPAUSAL WOMEN; RISK; MENOPAUSE; COHORT; SEX; AGE; ASSOCIATION; MORTALITY;
D O I
10.1016/j.parkreldis.2014.08.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Parkinson's disease (PD) is consistently observed to occur less frequently in women than men, prompting investigation into whether estrogen protects against neurodegeneration of dopaminergic neurons. Methods: We used baseline data in the California Teachers Study, a prospective cohort of women, to investigate whether reproductive factors indicating higher long-term estrogen levels are associated with PD using a nested case-control approach. We identified 228 PD cases and 3349 unaffected controls frequency matched by age and race. Results: Women who reported using combined estrogen/progesterone therapy or progesterone only formulations had a 57% increase in PD risk (OR = 1.57, 95% CI = 1.06, 2.34) compared to never having used HT. Compared to women with menopause at 50-52 years, menopause at younger (<35-46 years: OR = 0.59, 95% CI = 0.37, 0.94) and older ages (>= 53 years: OR = 0.54, 95% CI = 0.36, 0.83) had lower PD risk. A derived composite estrogen summary score for women's exposure to both endogenous and exogenous estrogens throughout life indicated that women with presumed higher cumulative lifetime levels of estrogen (a score of 3-5) had a significantly reduced PD risk [(OR = 0.57, 95% CI = 0.35, 0.91) relative to those with lower lifetime estrogen exposure or a composite estrogen summary score of 0-1]. Conclusions: These results provide some support for the hypothesis that lifelong high estrogen is protective in PD, suggesting that the level and persistence of exposure over the long term may be important in PD risk reduction. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1149 / 1156
页数:8
相关论文
共 33 条
[1]   Coffee consumption, gender, and Parkinson's disease mortality in the Cancer Prevention Study II cohort: The modifying effects of estrogen [J].
Ascherio, A ;
Weisskopf, MG ;
O'Reilly, EJ ;
McCullough, ML ;
Calle, EE ;
Rodriguez, C ;
Thun, MJ .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2004, 160 (10) :977-984
[2]   Caffeine, postmenopausal estrogen, and risk of Parkinson's disease [J].
Ascherio, A ;
Chen, H ;
Schwarzschild, MA ;
Zhang, SM ;
Colditz, GA ;
Speizer, FE .
NEUROLOGY, 2003, 60 (05) :790-795
[3]   Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case-control study [J].
Benedetti, MD ;
Maraganore, DM ;
Bower, JH ;
McDonnell, SK ;
Peterson, BJ ;
Ahlskog, JE ;
Schaid, DJ ;
Rocca, WA .
MOVEMENT DISORDERS, 2001, 16 (05) :830-837
[4]   High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States) [J].
Bernstein, L ;
Allen, M ;
Anton-Culver, H ;
Deapen, D ;
Horn-Ross, PL ;
Peel, D ;
Pinder, R ;
Reynolds, P ;
Sullivan-Halley, J ;
West, D ;
Wright, W ;
Ziogas, A ;
Ross, RK .
CANCER CAUSES & CONTROL, 2002, 13 (07) :625-635
[5]   AGE AT MENARCHE AND ESTROGEN CONCENTRATIONS OF ADULT WOMEN [J].
BERNSTEIN, L ;
PIKE, MC ;
ROSS, RK ;
HENDERSON, BE .
CANCER CAUSES & CONTROL, 1991, 2 (04) :221-225
[6]   Neuroprotective actions of sex steroids in Parkinson's disease [J].
Bourque, Melanie ;
Dluzen, Dean E. ;
Di Paolo, Therese .
FRONTIERS IN NEUROENDOCRINOLOGY, 2009, 30 (02) :142-157
[7]   Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP+) towards dopaminergic mesencephalic neurones in primary culture [J].
Callier, S ;
Le Saux, M ;
Lhiaubet, AM ;
Di Paolo, T ;
Rostène, W ;
Pelaprat, D .
JOURNAL OF NEUROCHEMISTRY, 2002, 80 (02) :307-316
[8]   Lifetime cumulative number of menstrual cycles and serum sex hormone levels in postmenopausal women [J].
Chavez-MacGregor, Mariana ;
van Gils, Carla H. ;
van der Schouw, Yvonne T. ;
Monninkhof, Evelyn ;
van Noord, Paulus A. H. ;
Peeters, Petra H. M. .
BREAST CANCER RESEARCH AND TREATMENT, 2008, 108 (01) :101-112
[9]   Postmenopausal estrogen use affects risk for Parkinson disease [J].
Currie, LJ ;
Harrison, MB ;
Trugman, JM ;
Bennett, JP ;
Wooten, GF .
ARCHIVES OF NEUROLOGY, 2004, 61 (06) :886-888
[10]   Inhibition of striatal dopamine transporter activity by 17β-estradiol [J].
Disshon, KA ;
Boja, JW ;
Dluzen, DE .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 345 (02) :207-211